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Abstract
Introduction
• The traditional approach to treating acute tendon injuries
and chronic tendinopathy is with anti-inflammatories, such
as NSAIDs, even though histopathological, biochemical
and molecular studies of damaged tendons have not
been able to demonstrate classical inflammatory
processes or components. In addition to that, at least one
study found that the early administration of ibuprofen in
the postoperative period was detrimental to tendon
healing. (Connizzo et al., 2014)
• Corticosteroid injections continue to be one of the most
commonly used approaches in treating tendinopathy and
other MSK soft tissue pathology. This treatment is
deemed to be very effective and provides relatively fast
and often long lasting pain relief. The cytotoxic side effect
of corticosteroids includes: degradation of fibroblasts,
cellular apoptosis, collagen necrosis, and deterioration of
mechanical properties of tendons. (Floyd Dean, Franklin,
Murphy, Javaid, & Carr, 2014)
• Surgical intervention. 
Research Questions
Literature Review
Applicability to Clinical 
Practice
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Discussion
• Contemporary Research
Since the mid 1980s, research on PROLO effects has
accelerated and the number and methodological quality of
studies assessing PROLO have increased dramatically.
Figure 1. Number of published clinical studies on PROLO since 1937. Adopted 
from Rabago, D., Slattengren, A., & Zgierska, A. (2010). Prolotherapy in Primary 
Care  Practice. Primary Care, 37(1), 65–80. 
http://doi.org/10.1016/j.pop.2009.09.013
• PROLO for knee osteoarthrosis: a randomized 
controlled trial
Trial parameters: Number of patients 93; duration of the trial
52 weeks; PROLO injections performed at 1,5,9,13,17
weeks; Western Ontario McMaster University Osteoarthritis
Index ( WOMAC) was used as primary outcome measure in
evaluating results (WOMAC is scored on a range of 0 to 100
points, with higher scores indicating better knee-related
quality of life)
Figure 2. Change in WOMAC composite scores over 52 weeks (± standard
error). Nonoverlapping confidence intervals indicate significance of change in
dextrose scores compared with change in scores of both saline (P<.05) and
exercise (P<.05) groups. Adopted from Rabago, D., Patterson, J. J., Mundt, M.,
Kijowski, R., Grettie, J., Segal, N. A., & Zgierska, A. (2013). Dextrose
Prolotherapy for Knee Osteoarthritis: A Randomized Controlled Trial. Annals of
Family Medicine, 11(3), 229–237.
http://doi.org/10.1370/afm.1504
RESULTS: At the end of the tracking period, week 52, there
was a statistically significant improvement on the WOMAC
score among the participants who received dextrose
PROLO injections. The score improved by more than 15
points, which corresponded to 24% compared with the
baseline score. These changes exceed the minimal clinical
important difference (MCID) on the WOMAC for the knee
osteoarthritis, which is set at 12 points.
Merriam-Webster defines prolotherapy (PROLO) as “an
alternative therapy for treating musculoskeletal pain that
involves injection of irritant substance (as dextrose) into a
ligament or tendon to promote the growth of new tissue”.
(2017) Experimental research and multiple clinical trials
have generated evidence suggesting that PROLO is
effective at treating a variety of musculoskeletal
conditions, including tendinopathies, joint instability and
ligament laxity. PROLO may also hold a potential to delay
or avoid joint replacement and rotator cuff surgeries.
Further research is needed to demonstrate the therapeutic
effect of PROLO unequivocally.
• What are the common MSK disorders that can potentially 
be treated with PROLO?
• What is the proposed mechanism of action behind? 
• What clinical studies are available in support of 
effectiveness and efficacy of PROLO? 
• What are the existing alternatives to PROLO and how do 
they compare with it? 
The information used for this project was retrieved from peer
reviewed periodicals that can be located at: PubMed,
SPORT Discus and Cochrane. The data regarding the
epidemiology and pathogenesis was collected from the
Centers for Disease Control and Prevention and the
Congressional Budget Office. The policies of the following
healthcare insurers were reviewed regarding the coverage of
PROLO: Aetna, United Healthgroup, and Blue Cross/Blue
Shield. The national non-coverage decision of the Centers of
Medicare and Medicaid Services regarding PROLO was
utilized for this project.
• MSK conditions are the single most common reason for
patients visiting their physician. (CDC)
• MSK conditions identified as amenable to PROLO: injured
or torn ligaments and tendons; chronic MSK pain,
including low back pain; tendinopathy; rotator cuff injuries,
and knee disorders.
• Pathophysiology factors: genetic component, repetitive 
micro trauma, no evidences for inflammatory 
processes or components. 
• Proposed intrinsic regeneration elements: growth factors,
cytokines and neuropeptides. (Riley, 2004)
• Proposed mechanism of action of PROLO – trigger of
inflammatory reaction: recruitment of granulocytes,
monocytes, macrophages and other inflammatory
mediators. Polypeptide growth factors attract fibroblasts
which deposit new collagen fibers at the site of PROLO
therapy. (Freeman et al., 2011) Having been injected with
hyperosmolar dextrose solutions, the cell becomes
dehydrated and releases lipids from cell membrane that
produce growth factors. (Reeves, 2015)
• At the present time, there is level I and/or level II
evidence demonstrating efficacy of PROLO for treating the
following conditions: knee (Rabago et al., 2013) and hand
osteoarthritis (Reeves & Hassanein, 2000), Osgood-
Schlatter disease (Topol et al., 2011), lateral epicondylitis
(Scarpone, Rabago, Zgierska, Arbogast, & Snell, 2008),
chronic low back pain (Yelland, Mar, Pirozzo, Schoene, &
Vercoe, 2004), anterior cruciate ligament laxity (Reeves &
Hassanein, 2003), and rotator cuff tendinopathy (Bertrand
et al., 2016).
• Prolotherapy at a glance
• Estimated cost of treatment
A typical PROLO protocol consists of 4 to 6 sessions, each
separated by intervals of 4 to 6 weeks. At the present time,
most insurers do not cover PROLO, and patients pay out-of-
pocket. The average cost of PROLO treatment ranges from
$1,125 for wrist/foot/hand disorders to $2,500 for back pain.
(Hauser, Baird 2010)
• PROLO coverage by insurance
The number of random controlled studies that explore the 
potential of PROLO continues to grow. Every single one of 
them has produced positive results supporting PROLO with 
additional studies needed to establish an unequivocal 
efficacy. However, most of these studies are self-funded and 
receive no financial support from any pharmaceutical or 
medical corporation. Therefore, it will likely take more time 
for the cumulative solid scientific evidence to reache a point 
when the insurance policy makers will no longer be able to 
ignore the PROLO potential. Major healthcare insurers, such 
as Aetna, United Healthgroup, and Blue Cross/Blue Shield, 
find the available data insufficient or have not recognized it, 
thus making PROLO inaccessible for most of the patients.
Statement of the Problem
• At the present time, PROLO is classified as an alternative
and/or complementary therapy. Therefore, it is not on the
list of services that are covered by commercial healthcare
insurance carriers.
• In 1999, the Centers of Medicare and Medicaid Services
(CMS) in their national non-coverage decision denied the
request for PROLO coverage citing the lack of conclusive
scientific evidence.
• In the last 15 years, a number of randomized controlled
trials produced clinically and statistically significant
evidence in support of PROLO. The studies were
published in a variety of established and recognized
medical periodicals.
• Will those new pieces of evidence turn out to be sufficient,
compelling and significant enough to sway the position
the medical establishment and the insurance carriers hold
regarding PROLO?
What is 
prolotherapy?
Prolotherapy is an injection-based complementary and alternative medical (CAM) therapy 
for chronic musculoskeletal pain. This treatment aims to stimulate a natural healing 
response at the site of painful soft tissue and joints.
What is involved? Prolotherapy treatment typically involves getting a series of 2–5 monthly injections of a 
topical anesthetic and a solution of other medicines directly on sore tendon or ligaments, 
or into painful joints.
What conditions is it 
used for, and is it 
effective?
Prolotherapy is generally used for musculoskeletal pain of greater than 3 months. 
Conditions that have responded well to prolotherapy in published studies include lateral 
epicondylitis, Achilles tendinopathy, and other overuse injuries involving tendons. 
Prolotherapy is also likely effective for knee osteoarthritis and low back pain, though 
studies assessing these conditions are less conclusive.
Is it safe? Studies indicate that prolotherapy is safe when performed by an experienced practitioner. 
It does not appear to have a greater risk than other injection techniques, such as steroid 
injections.
Does it hurt? No one loves getting a shot, though prolotherapy injections typically hurt less than most 
immunizations. Most patients tolerate prolotherapy injections related pain quite well with 
only topical and conservative measures. Physicians can pre-treat with a pain reliever if 
necessary.
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